Home>>Vafidemstat (ORY-2001)
Vafidemstat (ORY-2001) Catalog No.GC31101

Size Price Stock Qty
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 1357362-02-7 SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES NC1=NN=C(O1)CN[C@H]2[C@H](C3=CC=C(OCC4=CC=CC=C4)C=C3)C2
Formula C19H20N4O2 M.Wt 336.39
Solubility Soluble in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.

Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].

[1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.